Quick Takeaways
- TYNDALL CAPITAL PARTNERS L P filed SCHEDULE 13G/A for Cyclerion Therapeutics, Inc. Common Stock, no par value (CYCN).
- Disclosed ownership: 4.8%.
- Date of event: 30 Jun 2025.
TYNDALL CAPITAL PARTNERS L P - 30 Jun 2025 SCHEDULE 13G/A Report for Cyclerion Therapeutics, Inc. Common Stock, no par value (CYCN)
- Filing Manager
- TYNDALL CAPITAL PARTNERS L P
- Reporting Manager
- Tyndall Capital Partners, L.P.
- Symbol
- CYCN
- Shares outstanding
- 3,233,063 shares
- Disclosed Ownership
- 155,187 shares
- Ownership
- 4.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 16:05:22 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"TYNDALL CAPITAL PARTNERS L P disclosed 4.8% ownership in Cyclerion Therapeutics, Inc. Common Stock, no par value (CYCN) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Aug 2025, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Tyndall Capital Partners, L.P. | 4.8% | 155,187 | 155,187 | 0 | /s/ Jeffrey S. Halis | Jeffrey S. Halis, Manager of Jeffrey Management LLC, its general partner |